- Home
- KRG vs APLS Comparison
KRG vs APLS Comparison
Compare KRG & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | APLS |
|---|---|---|
| Founded | 1971 | 2009 |
| Country | United States | United States |
| Employees | 228 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.2B |
| IPO Year | 2004 | 2015 |
Fundamental Metrics
Financial Performance| Metric | KRG | APLS |
|---|---|---|
| Price | $27.77 | $41.05 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 21 |
| Target Price | $26.00 | ★ $33.59 |
| AVG Volume (30 Days) | 1.7M | ★ 17.1M |
| Earning Date | 04-29-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | ★ 6750.00 | 112.50 |
| EPS | 0.06 | ★ 0.15 |
| Revenue | $844,365,000.00 | ★ $1,003,782,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.96 | $18.19 |
| P/E Ratio | $454.83 | ★ $273.60 |
| Revenue Growth | 0.30 | ★ 28.46 |
| 52 Week Low | $20.86 | $16.83 |
| 52 Week High | $27.58 | $41.14 |
Technical Indicators
Market Signals| Indicator | KRG | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 67.93 | 84.57 |
| Support Level | $21.78 | $19.29 |
| Resistance Level | N/A | $41.14 |
| Average True Range (ATR) | 0.43 | 0.06 |
| MACD | 0.03 | -0.65 |
| Stochastic Oscillator | 97.36 | 58.33 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializing in high-quality, open-air shopping centers and mixed-use assets. Concentrated in the Sun Belt and strategic gateway markets, the company focuses on grocery-anchored, necessity-based retail. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About APLS Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).